Glaukos Corporation — News

GKOS' Q2 loss narrows as revenues jump 50% on iDose TR and Epioxa growth, lifting its 2026 sales outlook and shares by 9.8%.

zacks.com - 2026-07-30 12:56:07

Glaukos NYSE: GKOS reported record second-quarter 2026 consolidated net sales of $185.6 million, up 50% from the prior-year period on a reported basis and 49% on a constant-currency basis, as growth in its U.S. glaucoma, international glaucoma and corneal health businesses exceeded management's expectations.

marketbeat.com - 2026-07-30 00:05:25

Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

zacks.com - 2026-07-29 23:31:03

Glaukos Corporation (GKOS) Q2 2026 Earnings Call Transcript

seekingalpha.com - 2026-07-29 21:53:13

Glaukos (GKOS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.24 per share a year ago.

zacks.com - 2026-07-29 19:26:23

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the second quarter ended June 30, 2026. Key highlights include: Record net sales of $185.6 million in Q2 2026 increased 50% year-over-year on a reported basis and 49% year-over-year on a constant currency basis. Glaucoma record ne.

businesswire.com - 2026-07-29 16:05:00

Glaukos Corporation remains rated "Hold" as shares approach technical resistance near $160 ahead of the Q2 earnings release. Strong revenue growth—41%+ in Q1 and 38% YoY in Q3—has driven recent upgrades and fueled a 91% stock rally since last year. Key catalysts include potential Q2 revenue outperformance, guidance hikes above $640 million, and robust uptake of Epioxa and iDose TR.

seekingalpha.com - 2026-07-28 13:33:59

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the completion of patient enrollment in its U.S. 510(k) pivotal study evaluating the PRESERFLO™ MicroShunt in adult patients with primary open-angle glaucoma (POAG) who failed previous medical and surgical treatment. The PRESERFLO MicroShunt is a novel.

businesswire.com - 2026-07-27 07:00:00

Bank of New York Mellon Corp reduced its stake in shares of Glaukos Corporation (NYSE: GKOS) by 3.6% during the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 343,173 shares of the medical instruments supplier's stock after selling 12,667 shares during the period. Bank of New

defenseworld.net - 2026-07-26 04:29:36

Alex R. Thurman generated ~$1.6 million in gross proceeds by selling 10,000 shares at $155 per share on July 9. The disposition represented 19% of the insider's total equity holdings, including shares acquired through a concurrent option exercise.

fool.com - 2026-07-14 17:07:01

Abbott Laboratories offers a highly diversified healthcare portfolio with strong profitability across diagnostics and medical devices. Glaukos provides high-growth potential through its specialized focus on disruptive ophthalmic technologies for glaucoma and corneal care.

fool.com - 2026-07-08 17:03:46

GKOS has surged nearly 45% since May-end as upbeat iDose TR commentary, strong sales and growth expectations lift investor confidence.

zacks.com - 2026-07-08 15:05:28

This medical stock is in the buy zone of a base. The glaucoma treatment developer raised its revenue forecast in its latest earnings report.

investors.com - 2026-07-08 12:22:35

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release second quarter 2026 financial results after the market close on Wednesday, July 29, 2026. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on July 29, 2026.A link to the.

businesswire.com - 2026-07-08 07:00:00

Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and investors return from the long 4th of July holiday. With second-quarter earnings starting this week, and with all of the major indices trading at or near all-time highs, you... Here Are Monday's Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More

247wallst.com - 2026-07-06 07:52:28

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced completion of patient enrollment in its Phase 2 clinical study evaluating GLK-321 for the treatment of Demodex blepharitis. GLK-321 is an investigational drug candidate using Glaukos' proprietary iLution platform, a novel ophthalmic drug-delivery syste.

businesswire.com - 2026-06-25 07:00:00

Glaukos is riding strong on iDose TR growth and launching Epioxa into a large underpenetrated market, but reimbursement and competition risks persist.

zacks.com - 2026-06-05 15:16:14

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel Virtual Ophthalmology Forum on Tuesday, May 26, 2026, at 1:30 p.m. ET William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026, at.

businesswire.com - 2026-05-12 07:00:00